论文部分内容阅读
目的分析小剂量地西他滨(decitabine/dacogen,DAC)治疗异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation,allo-HSCT)后慢性移植物抗宿主病(chronic graft versus host disease,c GVHD)患者的转归情况。方法收集2013年6月25日至2015年7月7日我院行alloHSCT术后早期复发及发生c GVHD,并接受小剂量DAC治疗的4例患者,包括急性髓系白血病(acute myeloid leukemia,AML)3例,骨髓增生异常综合征(myelodysplastic syndrome,MDS)1例。对其诊断、移植方式、c GVHD分型及评分、以及DAC治疗后转归进行分析。结果 4例接受小剂量DAC的患者,c GVHD症状减轻,无严重的血液学毒性。1例因严重肺部感染放弃治疗,3例目前病情稳定。结论小剂量DAC可减轻allo-HSCT术后c GVHD症状,改善患者生存质量,并对早期复发的控制有一定的效果。
Objective To analyze the effects of low-dose decitabine / dacogen (DAC) on patients with chronic graft versus host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) The outcome of the situation. Methods A total of 4 patients with acute myeloid leukemia (AML), including early recurrence of alloHSCT, cGVHD and low-dose DAC in our hospital from June 25, 2013 to July 7, 2015 were enrolled in this study. ), 3 cases of myelodysplastic syndrome (MDS) in 1 case. The diagnosis, transplantation, c GVHD classification and score, as well as DAC after treatment outcome analysis. Results In 4 patients who received low-dose DAC, symptoms of cGVHD were relieved without serious hematologic toxicity. One patient gave up treatment due to severe pulmonary infection, and the other three were in stable condition at present. Conclusion Low-dose DAC can reduce the symptoms of cGVHD after allo-HSCT, improve the quality of life of patients and have a certain effect on the control of early recurrence.